Search research articles
Contact Us
Filters
Showing results (91-100 of 216) with videos related to
Page
of 22
Sort By:
Journal for Immunotherapy of Cancer
|
October 19, 2021
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
Sumit K Subudhi, Bilal A Siddiqui, Ana M Aparicio, et al.
Cancer Cell
|
September 11, 2020
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Padmanee Sharma, Russell K Pachynski, Vivek Narayan, et al.
Nature
|
March 22, 2017
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lu, James W Horner, Erin Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2021
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Ming Lei, Nathan O Siemers, Dimple Pandya, et al.
Science Translational Medicine
|
June 20, 2020
<i>ARID1A</i> mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
Sangeeta Goswami, Yulong Chen, Swetha Anandhan, et al.
Cancer Immunology Research
|
September 5, 2014
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Chad Tang, Xiaohong Wang, Hendrick Soh, et al.
Cell
|
April 14, 2023
Immune checkpoint therapy-current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell
|
September 27, 2016
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao, Lewis Zhichang Shi, Hao Zhao, et al.
Journal for Immunotherapy of Cancer
|
May 14, 2021
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
Meenal Sinha, Li Zhang, Sumit Subudhi, et al.
Nature Communications
|
January 7, 2026
Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer
Pratishtha Singh, Ranit D'Rozario, Bidisha Chakraborty, et al.
Page
of 22
Search research articles
Search
Showing results (91-100 of 216) with videos related to
Sort By:
Page
of 22
Journal for Immunotherapy of Cancer
|
October 19, 2021
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
Sumit K Subudhi, Bilal A Siddiqui, Ana M Aparicio, et al.
Cancer Cell
|
September 11, 2020
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Padmanee Sharma, Russell K Pachynski, Vivek Narayan, et al.
Nature
|
March 22, 2017
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lu, James W Horner, Erin Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2021
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Ming Lei, Nathan O Siemers, Dimple Pandya, et al.
Science Translational Medicine
|
June 20, 2020
<i>ARID1A</i> mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
Sangeeta Goswami, Yulong Chen, Swetha Anandhan, et al.
Cancer Immunology Research
|
September 5, 2014
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Chad Tang, Xiaohong Wang, Hendrick Soh, et al.
Cell
|
April 14, 2023
Immune checkpoint therapy-current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell
|
September 27, 2016
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao, Lewis Zhichang Shi, Hao Zhao, et al.
Journal for Immunotherapy of Cancer
|
May 14, 2021
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
Meenal Sinha, Li Zhang, Sumit Subudhi, et al.
Nature Communications
|
January 7, 2026
Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer
Pratishtha Singh, Ranit D'Rozario, Bidisha Chakraborty, et al.
Page
of 22